CY1111608T1 - Σκευασμα φλουπιρτινης για τη θεραπεια νευροεκφυλιστικων νοσων του οπτικου συστηματος και του σακχαρωδη διαβητη - Google Patents

Σκευασμα φλουπιρτινης για τη θεραπεια νευροεκφυλιστικων νοσων του οπτικου συστηματος και του σακχαρωδη διαβητη

Info

Publication number
CY1111608T1
CY1111608T1 CY20111100148T CY111100148T CY1111608T1 CY 1111608 T1 CY1111608 T1 CY 1111608T1 CY 20111100148 T CY20111100148 T CY 20111100148T CY 111100148 T CY111100148 T CY 111100148T CY 1111608 T1 CY1111608 T1 CY 1111608T1
Authority
CY
Cyprus
Prior art keywords
diseases
preparation
diabetes
neurocological
flupertinin
Prior art date
Application number
CY20111100148T
Other languages
English (en)
Inventor
Karl-Georg Schmidt
Original Assignee
Karl-Georg Schmidt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karl-Georg Schmidt filed Critical Karl-Georg Schmidt
Publication of CY1111608T1 publication Critical patent/CY1111608T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η εφεύρεση αφορά τη χρήση της φλουπιρτίνης για την παραγωγή ενός φαρμακευτικού σκευάσματος για τη θεραπεία και/ή την προφύλαξη από τον σακχαρώδη διαβήτη, τη διαβητική αμφιβληστροειδοπάθεια, τη διαβητική ωχροπάθεια, τις γενετικά καθοριζόμενες ωχροπάθειες, την απόπτωση του οπτικού συστήματος και/ή τα γλαυκώματα του ανθρώπου, καθώς και ένα συνδυασμένο σκεύασμα, το οποίο περιέχει φλουπιρτίνη καθώς και τουλάχιστον μία περαιτέρω δραστική ουσία για τη θεραπεία και/ή την προφύλαξη από τις αναφερόμενες νόσους.
CY20111100148T 2003-06-23 2011-02-09 Σκευασμα φλουπιρτινης για τη θεραπεια νευροεκφυλιστικων νοσων του οπτικου συστηματος και του σακχαρωδη διαβητη CY1111608T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10328260A DE10328260A1 (de) 2003-06-23 2003-06-23 Flupirtine-Präparat
EP04740166A EP1643997B1 (de) 2003-06-23 2004-06-22 Flupirtine-präparat zur behandlung von neurodegenerativen erkrankungen des sehapparates und von diabetes mellitus

Publications (1)

Publication Number Publication Date
CY1111608T1 true CY1111608T1 (el) 2015-10-07

Family

ID=33546620

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100148T CY1111608T1 (el) 2003-06-23 2011-02-09 Σκευασμα φλουπιρτινης για τη θεραπεια νευροεκφυλιστικων νοσων του οπτικου συστηματος και του σακχαρωδη διαβητη

Country Status (14)

Country Link
US (1) US20060205793A1 (el)
EP (1) EP1643997B1 (el)
JP (1) JP4921165B2 (el)
CN (2) CN102940633A (el)
AT (1) ATE487513T1 (el)
CY (1) CY1111608T1 (el)
DE (2) DE10328260A1 (el)
DK (1) DK1643997T3 (el)
ES (1) ES2356244T3 (el)
PL (1) PL1643997T3 (el)
PT (1) PT1643997E (el)
SI (1) SI1643997T1 (el)
WO (1) WO2005000306A1 (el)
ZA (1) ZA200600472B (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005054610B4 (de) * 2005-11-08 2010-06-10 Awd.Pharma Gmbh & Co. Kg Flupirtin enthaltende Arzneimittelzubereitung mit kontrollierter Wirkstofffreisetzung
CN102836156A (zh) * 2012-09-03 2012-12-26 天津红日药业股份有限公司 一种含马来酸氟吡汀的胶囊及其制备方法
CN104083335B (zh) * 2013-07-31 2015-11-11 成都苑东药业有限公司 一种马来酸氟吡汀胶囊组合物及其制备方法
CN107412186A (zh) * 2017-08-02 2017-12-01 瑞阳制药有限公司 含马来酸氟吡汀的组合物及其制备方法
CN109806243B (zh) * 2017-11-20 2022-07-15 北京泰德制药股份有限公司 一种含有氟吡汀或其药用盐的皮肤外用贴剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1A (en) * 1836-07-13 John Ruggles Locomotive steam-engine for rail and other roads
EP0189788B1 (de) * 1985-01-23 1989-09-13 ASTA Pharma Aktiengesellschaft Synergistische Kombination von Flupirtin und nicht-steroidalen Antiphlogistika
GB8625941D0 (en) * 1986-10-30 1986-12-03 Sandoz Ltd Substituted alpha-amino acids
IT1256022B (it) * 1992-06-08 1995-11-20 Preparazioni farmaceutiche stabili di nicorandil
DE4319649A1 (de) * 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
DE19625582A1 (de) * 1996-06-27 1998-01-02 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen die mit einer unphysiologisch hohen Zellsterberate einhergehen
JP4372905B2 (ja) * 1999-09-02 2009-11-25 興和株式会社 網膜神経細胞保護剤
ZA200108038B (en) * 2000-10-02 2003-04-01 Pfizer Prod Inc Prophylactic use of n-methyl-d-asparrate (NMDA) antagonists.

Also Published As

Publication number Publication date
US20060205793A1 (en) 2006-09-14
DK1643997T3 (da) 2011-02-28
ES2356244T3 (es) 2011-04-06
CN1838955A (zh) 2006-09-27
JP2008529961A (ja) 2008-08-07
ATE487513T1 (de) 2010-11-15
SI1643997T1 (sl) 2011-04-29
PT1643997E (pt) 2011-02-16
PL1643997T3 (pl) 2011-05-31
CN102940633A (zh) 2013-02-27
WO2005000306A1 (de) 2005-01-06
EP1643997B1 (de) 2010-11-10
ZA200600472B (en) 2007-05-30
EP1643997A1 (de) 2006-04-12
JP4921165B2 (ja) 2012-04-25
DE502004011874D1 (de) 2010-12-23
DE10328260A1 (de) 2005-01-27

Similar Documents

Publication Publication Date Title
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
MXPA04011612A (es) Uso oftalmologico de roflumilasto para el tratamiento de enfermedades del ojo.
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
CY1111608T1 (el) Σκευασμα φλουπιρτινης για τη θεραπεια νευροεκφυλιστικων νοσων του οπτικου συστηματος και του σακχαρωδη διαβητη
CY1110606T1 (el) Χρηση των ανταγωνιστων της il-23 και il-17 για τη θεραπεια της αυτοανοσης οφθαλμικης φλεγμονωδους νοσου
EA200000747A1 (ru) СПОСОБ ВВЕДЕНИЯ AspB28-ИНСУЛИНА ЧЕЛОВЕКА
NO20064186L (no) Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod
ATE355065T1 (de) Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
WO2006072589A3 (en) Disubstituted ureas as kinase inhibitors
DK1412368T3 (da) Sukkerderivater af hydromorfon, dihydromorfin, dihydroisomorfin, sammensætninger deraf og anvendelser til behandling eller forebyggelse af smerter
GB0211649D0 (en) Organic compounds
DE502005008790D1 (de) Substituierte phenylaminopyrimidine
NO20050718L (no) Topikal behandling av hudsykdommer
ATE508738T1 (de) System zur beabstandeten abgabe von arzneimitteln
NO20064521L (no) Framgangsmate og blanding for behandling av rhinitt
DE60334147D1 (de) Plazentäre alkalische phosphatase zur diabeteskontrolle
BRPI0607680A2 (pt) agente profilático/terapêutico para anormalidades do metabolismo de açúcar/lipìdio
CY1110369T1 (el) Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
WO2009003694A3 (en) Method for treating diseases related to mitochondrial dysfunction
PT1343472E (pt) Pulverizacao nasal tixotropica
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
IS8373A (is) Notkun oxkarbasepíns til að meðhöndla sársauka vegna sykursýkisfjöltauga-kvilla og til að bæta svefn
PT1220676E (pt) Prevencao do cancro colorrectal